Daniela Mihic-Probst

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma
    Daniela Mihic-Probst
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Int J Cancer 121:1764-70. 2007
  2. ncbi request reprint Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus
    Daniela Mihic-Probst
    Department of Pathology, University Hospital, Zurich
    Virchows Arch 443:745-51. 2003
  3. ncbi request reprint CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma
    Daniela Mihic-Probst
    Department of Pathology, University Hospital, Zurich, Switzerland
    Anticancer Res 24:19-26. 2004
  4. ncbi request reprint Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma
    Daniela Mihic-Probst
    Department of Pathology, University Hospital, Zurich, Switzerland
    Anticancer Res 24:2415-8. 2004
  5. pmc Tumor cell plasticity and angiogenesis in human melanomas
    Daniela Mihic-Probst
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    PLoS ONE 7:e33571. 2012
  6. pmc Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients
    Alessandra Curioni-Fontecedro
    Division of Internal Medicine and Clinic of Oncology, University Hospital, Zurich, Switzerland
    PLoS ONE 6:e21418. 2011
  7. doi request reprint Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
    Peter Schraml
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Oncol Rep 28:654-8. 2012
  8. pmc Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
    Nicola L Schoenewolf
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Case Rep Oncol 5:280-9. 2012
  9. doi request reprint Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth
    Gianluca Civenni
    Institute of Anatomy and Biostatistics Unit ISPM, University of Zurich, Zurich, Switzerland
    Cancer Res 71:3098-109. 2011
  10. ncbi request reprint p16 expression in primary malignant melanoma is associated with prognosis and lymph node status
    Daniela Mihic-Probst
    Department of Pathology, Institute of Surgical Pathology, University Hospital, Zurich, Switzerland
    Int J Cancer 118:2262-8. 2006

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma
    Daniela Mihic-Probst
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Int J Cancer 121:1764-70. 2007
    ..005). This suggests that BMI-1 mediated repression of p16(ink4a) may contribute to an increased aggressive behavior of stem cell-like melanoma cells...
  2. ncbi request reprint Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus
    Daniela Mihic-Probst
    Department of Pathology, University Hospital, Zurich
    Virchows Arch 443:745-51. 2003
    ..In contrast, all cells of melanoma metastases, except one skin metastasis, lacked nuclear staining for p16. These findings indicate that p16 is a reliable marker to distinguish lymph-node nevi from melanoma metastasis...
  3. ncbi request reprint CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma
    Daniela Mihic-Probst
    Department of Pathology, University Hospital, Zurich, Switzerland
    Anticancer Res 24:19-26. 2004
    ..Atypical fibroxanthoma (AFX) and undifferentiated high grade pleomorphic sarcoma (UpS) are histologically very similar, if not identical. However, they differ significantly in clinical outcome...
  4. ncbi request reprint Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma
    Daniela Mihic-Probst
    Department of Pathology, University Hospital, Zurich, Switzerland
    Anticancer Res 24:2415-8. 2004
    ..Distinction of Spitz nevus from malignant melanoma is sometimes difficult on the basis of conventional histology. A high rate of BRAF gene mutations in malignant melanomas (66%) and nevi (82%) has recently been reported...
  5. pmc Tumor cell plasticity and angiogenesis in human melanomas
    Daniela Mihic-Probst
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    PLoS ONE 7:e33571. 2012
    ..0001). We suggest that the hypoxic microenvironment in metastases contributes to a phenotype switch allowing melanoma cells to physically contribute to blood vessel formation...
  6. pmc Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients
    Alessandra Curioni-Fontecedro
    Division of Internal Medicine and Clinic of Oncology, University Hospital, Zurich, Switzerland
    PLoS ONE 6:e21418. 2011
    ..01). Our results suggest that the expression of MAGE-C1/CT7 and MAGE-C2/CT10 in primary melanoma is a potent predictor of sentinel lymph node metastasis...
  7. doi request reprint Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
    Peter Schraml
    Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Oncol Rep 28:654-8. 2012
    ..The MGMT promoter methylation status may be a promising predictive marker for temozolomide therapy in metastatic melanoma patients. Larger sample sizes may help to validate significant differences in survival type endpoints...
  8. pmc Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques
    Nicola L Schoenewolf
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Case Rep Oncol 5:280-9. 2012
    ..Melanoma is characterized by a high frequency of BRAF mutations. It is unknown if the BRAF mutation status has any predictive value for therapeutic approaches such as angiogenesis inhibition...
  9. doi request reprint Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth
    Gianluca Civenni
    Institute of Anatomy and Biostatistics Unit ISPM, University of Zurich, Zurich, Switzerland
    Cancer Res 71:3098-109. 2011
    ....
  10. ncbi request reprint p16 expression in primary malignant melanoma is associated with prognosis and lymph node status
    Daniela Mihic-Probst
    Department of Pathology, Institute of Surgical Pathology, University Hospital, Zurich, Switzerland
    Int J Cancer 118:2262-8. 2006
    ..Therefore, immunohistochemical evaluation for p16 expression is of potential value for treatment planning in melanoma surgery...
  11. pmc Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients
    Simone M Goldinger
    Dermatology and Pathology Departments, University Hospital of Zurich, Zurich, Switzerland
    Eur J Immunol 42:3049-61. 2012
    ..We conclude that the simultaneous use of both Imiquimod and CpG-ODN induced combined memory and effector CD8(+) T-cell responses...
  12. doi request reprint The causes of the nasolabial crease: a histomorphological study
    Gertrude M Beer
    Institute of Anatomy, Department of Macroscopic Anatomy, University of Zurich Irchel, Zurich, Switzerland
    Clin Anat 26:196-203. 2013
    ..Botulinum toxin injected intradermally into the nasolabial crease might constitute a new treatment option to minimize or even eradicate the crease and the fold...
  13. ncbi request reprint Immunohistochemical differentiation and localization analysis of sweat glands in the adult human axilla
    Gertrude M Beer
    Division for Plastic, Hand, and Reconstructive Surgery, Department of Surgery, Institute of Clinical Pathology, University Hospital Zurich, Zurich, Switzerland
    Plast Reconstr Surg 117:2043-9. 2006
    ..To define the different types of sweat glands and their location and number, the authors carried out a prospective histologic study on adult human axillary skin, including various immunohistochemical markers...
  14. doi request reprint HER3 is a determinant for poor prognosis in melanoma
    Markus Reschke
    Department of Molecular Biology, Max Planck Institute of Biochemistry, Munich, Germany
    Clin Cancer Res 14:5188-97. 2008
    ..However, the relevance of HER3 with regard to its prognostic significance and function in primary melanoma and metastases remains largely elusive...